ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
47 announcements with these filters
Metropolis Healthcare increased paid‑up share capital by ₹0.01 Crore through re‑issue of forfeited shares. The capital now stands at approximately ₹41.47 Crore.
Metropolis Healthcare allotted 36,900 equity shares at ₹2 each, amounting to ₹73,800 (≈0.01 Cr) under its 2020 RSU plan. The shares rank pari‑passu with existing equity.
Metropolis reported 16% YoY revenue growth in Q1FY27, driven by patient volumes and product mix. TruHealth and Specialty segments led growth; EBITDA margins improved YoY.
Metropolis Healthcare submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report confirms overall regulatory compliance with no material deviations.
Metropolis Healthcare reports strong FY26 performance with 23.6% YoY revenue growth and 24.4% EBITDA margin. Strategy focuses on network productivity, genomics, and expanding 'mini hubs' for pathology and basic radiology.
Metropolis Healthcare shows strong organic momentum, beating FY26 revenue guidance. Management is shifting focus from aggressive lab expansion to productivity-led growth and margin recovery through operating leverage.
Metropolis Healthcare corrected a reporting error in its historical consolidated profit figures. This administrative update ensures financial transparency without impacting current year results.
Metropolis Healthcare approved Deloitte Haskins & Sells as statutory auditors for a five-year term. President Nilesh Shah transitions to an advisory role, ceasing as Senior Management Personnel.
Metropolis Healthcare reported Q4FY26 revenue of ₹425 Crore, up 23% YoY. Strong growth across B2C and B2B segments drove a 75% rise in profit.
Metropolis Healthcare reports strong FY26 growth, with Group Revenue up 24% and PAT up 31% YoY. The company is executing its 'Metropolis 3.0' strategy focused on specialty tests and network expansion.
Metropolis Healthcare declared an interim dividend of ₹1 per equity share for FY 2025-26. The record date is set for May 19, 2026.
Metropolis Healthcare Ltd reported revenue from operations of ₹424.7 Cr (+23.0% YoY) and net profit of ₹51 Cr (+74.7% YoY) for Q4 FY26.
Metropolis Healthcare reported its financial results and declared an interim dividend totaling ₹20.73 Crore. The board also recommended Deloitte Haskins & Sells as new statutory auditors.
Metropolis Healthcare allotted 4,200 equity shares and granted 2,26,581 new stock benefits. The ₹0.00084 Crore allotment follows employee stock option exercises and RSU plan vesting.
Metropolis Healthcare Ltd has scheduled a Board Meeting for May 13, 2026. The board will consider audited FY26 financial results and the declaration of a second interim dividend for FY26. Consequently, the company's trading window remains closed until May 15, 2026.
Metropolis Healthcare Limited submitted its quarterly compliance certificate for the period ended March 31, 2026, as per SEBI (Depositories and Participants) Regulations. The certificate, issued by its registrar MUFG Intime India, confirms that security certificates received for dematerialisation were processed and listed on the stock exchanges within prescribed timelines.
Metropolis Healthcare reported ~23% Y-o-Y consolidated revenue growth for Q4FY26, driven by the TruHealth wellness and specialized testing segments. B2B and B2C channels grew 30% and 19% respectively. Organic revenue increased ~14.5%, supported by improved EBITDA margins and volume growth across diagnostic segments.